|
An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD). |
|
|
Honoraria - Amgen; Astellas Pharma; Janssen; Merck; Sanofi; Takeda |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Amgen |
|
|
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc. |
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc. |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst) |
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst) |
|
|
Honoraria - Exelixis; Genentech/Roche |
Consulting or Advisory Role - Exelixis; Genentech/Roche |
Speakers' Bureau - Exelixis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen Oncology |
Consulting or Advisory Role - Bayer; Ferring; Millennium |
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME |
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio |
Expert Testimony - Celgene; sanofi |